22
POPSPotential Alzheimer's, Parkinson's Cure Found In Century-old Drug Also impressed is one of Dr. Atamna's co-authors, Bruce Ames, PhD, a senior scientist at Children's and world-renowned expert in nutrition and aging. "What we potentially have is a wonder drug." said Dr. Ames. "To find that such a common and inexpensive drug can be used to increase and prolong the quality of life by treating such serious diseases is truly exciting." Dr. Atamna's research is the first to show that low concentrations of the drug have the ability to slow cellular aging in cultured cells in the laboratory and in live mice. He believes methylene blue has the potential to become another commonplace low-cost treatment like aspirin, prescribed as a blood thinner for people with heart disorders.
15
POPSScientists stop the aging process. Perhaps suspend. In a mouse liver. The findings linked aging to the ability of cells to expel toxins,which when not removed cause a buildup which results in degeneration. The degeneration then reducing the ability to remove toxins. The toxins that are removed are generally natural, but I don't know how the results would extend to artificial toxins which are leeching through our environments.
0
POPSStem cell therapy The potential applications of stem cell therapy include: leukemia, sickle-cell anemia, Parkinson's disease, Alzheimer's disease, burns, diabetes, cirrhosis of liver etc.
0
POPSStem Cells 2.0: Scientists Make Revolutionary Advance First paragraph. A while back scientists were making revolutionary breakthroughs in stem cell research. Unfortunately they fell foul of interpretations of thousand year old texts in foreign languages, and a government with the scientific understanding of a squashed grape said "Sorry, our kind and loving God requires that people continue to suffer from Parkinson's, anemia, and various other horrible ailments." Luckily, scientists are awesome and did the obvious thing - make ANOTHER revolutionary breakthrough to get around the problem.
10
POPSAzilect (drug) proven to slow Parkinson's Teva intends to submit these results to the regulatory authorities in the US and Europe. Based on these results, the drug could become the first Parkinson's disease treatment in the world to receive a label for "disease modification." Azilect received the approval of the US Food and Drug Administration for sale in the spring of 2006.
0
POPSAcadia Schizophrenia Drug Fails Acadia does a nice job not spinning the results. (See the press release below.) The company has another drug, pimavanserin, in trials for psychosis related to Parkinson's. That drug is also being tested for schizophrenia as an add-on to other therapies. What's interesting is that the failed drug, ACP-104, was a metabolite of Clozapine, a very effective antipsychotic with harsh side effects. In theory, using the metabolite should result in a better drug, but it doesn't always work out this way. Sometimes, as in this case, you get something that's not effective at all. That's a painful reminder of how little we know about biology and chemistry and how much sheer luck is still involved in inventing new medicines.
4
Pops
Newest Clips
Latest Comments
Most Pops
Print
Save
Turn on live update